Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May 24;366(21):1968-77.
doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

Idiopathic Pulmonary Fibrosis Clinical Research Network; Ganesh Raghu, Kevin J Anstrom, Talmadge E King Jr, Joseph A Lasky, Fernando J Martinez
Collaborators
Randomized Controlled Trial

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

Idiopathic Pulmonary Fibrosis Clinical Research Network et al. N Engl J Med. .

Abstract

Background: A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. The safety and efficacy of this three-drug regimen is unknown.

Methods: In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups -- receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo -- in a 1:1:1 ratio. The primary outcome was the change in longitudinal measurements of forced vital capacity during a 60-week treatment period.

Results: When approximately 50% of data had been collected (with 77 patients in the combination-therapy group and 78 in the placebo group), a planned interim analysis revealed that patients in the combination-therapy group, as compared with the placebo group, had an increased rate of death (8 vs. 1, P=0.01) and hospitalization (23 vs. 7, P<0.001). These observations, coupled with no evidence of physiological or clinical benefit for combination therapy, prompted the independent data and safety monitoring board to recommend termination of the combination-therapy group at a mean follow-up of 32 weeks. Data from the ongoing comparison of the NAC-only group and the placebo group are not reported here.

Conclusions: Increased risks of death and hospitalization were observed in patients with idiopathic pulmonary fibrosis who were treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo. These findings provide evidence against the use of this combination in such patients. (Funded by the National Heart, Lung, and Blood Institute and the Cowlin Family Fund; ClinicalTrials.gov number, NCT00650091.).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Enrollment and Outcomes
DLCO denotes carbon monoxide diffusing capacity, FVC forced vital capacity, IPF idiopathic pulmonary fibrosis, and NAC N-acetylcysteine.
Figure 2
Figure 2. Kaplan–Meier Curves for the Time until Death, Disease Progression, or Hospitalization
Shown are the time until death (Panel A), until a composite of death or disease progression (defined as a decrease in the forced vital capacity of ≥10%) (Panel B), or until a composite of death or hospitalization (Panel C). Combination therapy refers to a three-drug regimen consisting of prednisone, azathioprine, and N-acetylcysteine.
Figure 3
Figure 3. Timeline until Death during the 60-Week Study Period, According to Study Group
Shown are follow-up data for patients from randomization until death (from left to right). Each set of bars represents one patient who died, including eight patients receiving combination therapy and one patient receiving matched placebo. For each patient, three bars are plotted (for N-acetylcysteine [NAC], azathioprine, and prednisone), with darker shading indicating the interval in which the drug was administered and lighter shading indicating the interval in which the drug was not administered. The dark vertical lines with a corresponding number indicate the occurrence of a serious adverse event (SAE), as listed.
See this image and copyright information in PMC

Comment in

Similar articles

  • Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
    Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Idiopathic Pulmonary Fibrosis Clinical Research Network, et al. N Engl J Med. 2014 May 29;370(22):2093-101. doi: 10.1056/NEJMoa1401739. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836309 Free PMC article. Clinical Trial.
  • High-dose acetylcysteine in idiopathic pulmonary fibrosis.
    Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFIGENIA Study Group. Demedts M, et al. N Engl J Med. 2005 Nov 24;353(21):2229-42. doi: 10.1056/NEJMoa042976. N Engl J Med. 2005. PMID: 16306520 Clinical Trial.
  • Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
    Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G; IFIGENIA study group. Behr J, et al. Respir Res. 2009 Oct 27;10(1):101. doi: 10.1186/1465-9921-10-101. Respir Res. 2009. PMID: 19860915 Free PMC article. Clinical Trial.
  • Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.
    Nathan SD. Nathan SD. Clin Chest Med. 2006 Mar;27(1 Suppl 1):S27-35, vi. doi: 10.1016/j.ccm.2005.08.004. Clin Chest Med. 2006. PMID: 16545630 Review.
  • Current perspectives on the treatment of idiopathic pulmonary fibrosis.
    Walter N, Collard HR, King TE Jr. Walter N, et al. Proc Am Thorac Soc. 2006 Jun;3(4):330-8. doi: 10.1513/pats.200602-016TK. Proc Am Thorac Soc. 2006. PMID: 16738197 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
    1. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med. 2000;161:646–64. - PubMed
    1. Peikert T, Daniels C, Beebe T, Meyer K, Ryu JH. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med. 2008;102:1342–8. - PubMed
    1. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229–42. - PubMed
    1. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2285–7. - PubMed

Publication types

MeSH terms

Associated data